Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.

Objectives: To evaluate the cost effectiveness of dolutegravir + abacavir/lamivudine (DTG + ABC/3TC) compared with raltegravir + abacavir/lamivudine (RAL + ABC/3TC) and ritonavir-boosted darunavir + abacavir/lamivudine (DRV/r + ABC/3TC) in HIV-1-infected treatment-naive patients in Russia.

Methods: A dynamic Markov model was developed with five response states and six CD4-based health states. Efficacy estimated as probability of viral suppression (HIV RNA <50 copies/ml) at 48 weeks was obtained from a published network meta-analysis.

[STUDY OF SAFETY OF PAROTITIS VACCINE].

Aim: Monitoring of post-vaccinal complications in children immunized with a parotitis vaccine.

Materials And Methods: Observation of 198 945 children, immunized with 16 lots of parotitis vaccine with Leningrad-3 strain (L-3), was carried out for 3 years. Paired samples of sera and saliva were obtained from children, in whom adverse events were registered for 42 days after vaccination.

[The first experience of application of standardized genotype technique of identification of HIV-tropism].

The antagonists of co-receptor CCR5 are an ultimately new class of preparations to treat HIV-infection. The mechanism of action of the preparations of this class is in the selective binding with co-receptor CCR5. This process results in the prevention of penetration of HIV into cell.

[Comparative evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus].

Two enzyme immunoassays (ELISA) for mumps antibody detection using the Enzygnost (Germany) and Parotit-screen (Russia) were comparatively assayed using sera of randomly assigned 70 healthy young adult volunteers. The neutralization test (NT) was performed for all sera using mumps viruses (MVs) of the relevant strains Enders and Leningrad-3. The proportion of positive results was significantly higher with the Parotit-screen than with the Enzygnost (80% versus 52.

Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge.

Bacterial ghosts (BGs) have been applied through oral, aerogenic, intraocular or intranasal routes for mucosal immunization using a wide range of experimental animals. All these applications required a booster after primary immunization to achieve protective immunity against the lethal challenge. Here we report for the first time that a single rectal dose of BGs produced from enterohaemorrhagic Escherichia coli (EHEC) O157:H7 fully protects mice against a 50% lethal challenge with a heterologous EHEC strain given at day 55.